In the wake of the tragic aircraft crash at Milestone School and College in Uttara, Beximco Pharmaceuticals Ltd. has taken urgent steps to support the treatment of victims suffering from severe burns and injuries.
In response to this national tragedy, today (22 July) Beximco Pharma has donated 5,500 packs of Bactrobex (Mupirocin) ointment and 15,500 packs of Burnsil ointment to several key hospitals treating the injured.
The support is directed toward to Uttara Adhunik Hospital, Kuwait Moitri Hospital, Monsur Ali Hospital, National Institute of Burn and Plastic Surgery and Burn & Plastic Surgery Unit, Dhaka Medical College Hospital (DMCH)
These topical medications are vital in preventing infections and promoting healing in burn wounds, and are expected to significantly aid in the treatment and recovery of the affected patients.
As a company committed to public health, Beximco Pharma doing everything in their capacity to support the medical teams working tirelessly to save lives and treat the injured.
Beximco Pharma remains committed to standing by the nation in times of crisis and will continue to coordinate with healthcare providers to provide any further support required.
The devastating incident, which occurred on Monday when a Bangladesh Air Force F-7 aircraft crashed into a building of the Milestone School and College, has claimed the lives of at least 31 people and injured 165 others, according to the Inter-Services Public Relations (ISPR).
About Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals is a leading manufacturer and exporter of medicines in Bangladesh, recognized for its innovation, global reach, and commitment to high-quality, affordable medicines. Incorporated in 1976, the company began by importing products from Bayer (Germany) and Upjohn (USA), later manufacturing them under license.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by major global regulatory authorities, including those of the U.S.A., Europe, Australia, Canada, GCC and Latin America. The company operates in over 60 countries and is the first Bangladeshi pharmaceutical company to receive U.S. FDA approval. It is also the only Bangladeshi company listed on the AIM of London Stock Exchange. In April 2018, Beximco Pharma acquired 85.2% stake in Nuvista Pharma (formerly Organon Bangladesh Ltd.), followed by a 54.6% stake in Sanofi Bangladesh Ltd. (now Synovia Pharma) in October 2021.
Recognized with numerous accolades, Beximco Pharma was named in Forbes Asia’s Best Under a Billion 2023, and has won prestigious awards such as the CPhI Pharma Awards for COVID-19 innovation, Global Generics and Biosimilars Awards for ‘Company of the Year’ (2019, 2021), SCRIP Awards for Best Company in and Emerging Market (2021) & Community partnership of the Year (2018) and nine-time recipient of the Bangladesh National Export(Gold) Trophy.
With a workforce of over 5,900 and a portfolio of more than 500 products, Beximco Pharma continues to drive pharmaceutical innovation, expanding access to high-quality and affordable medicine worldwide.
